# Oral Guanabenz for Multiple Sclerosis

> **NCT02423083** · PHASE1 · TERMINATED · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 2 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis

## Interventions

- **DRUG:** Guanabenz

## Key facts

- **NCT ID:** NCT02423083
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04-21
- **Primary completion:** 2017-10-30
- **Final completion:** 2017-10-30
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2019-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02423083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02423083, "Oral Guanabenz for Multiple Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02423083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*